What is the main use of Mobotinib succinate (Mobosetinib)?

Mobosetinib succinate (mobosetinib) is primarily used to treat certain types of lung cancer. Specifically, it is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed during or after platinum-containing chemotherapy. The emergence of this drug provides new treatment options for these patients and significantly improves their quality of life and survival period.

Mobosetinib is the world's first and currently only approved oral targeted drug for the treatment of EGFR 20 advanced non-small cell lung cancer with exon insertion mutations. EGFR is a key factor in the growth and division of lung cancer cells, and exon 20 insertion mutation is a relatively rare type of gene mutation. Mobosetinib can specifically target this mutation and inhibit tumor growth by inhibiting the activity of EGFR and blocking the signal transduction of tumor cells.

Because EGFR 20 patients with exon insertion mutations often lacked effective treatments in the past, and traditional chemotherapy and radiotherapy had limited effects and had serious side effects. The emergence of moboxetinib provides a new treatment strategy for these patients, significantly improving their quality of life and survival. Its advantages of high affinity, potent inhibition and precise selection allow the drug to more effectively bind to EGFR exon 20 insertion mutations, thus overcoming clinical problems.

Mobosetinib is an oral drug, which brings great convenience to patients. Compared with traditional treatment methods that require long hospitalization and intravenous infusion, oral administration is undoubtedly simpler and more convenient, and does not affect the patient's daily life.